Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19066279 | EXOSOME SYSTEMS, PRODUCTS AND METHODS | February 2025 | April 2025 | Allow | 1 | 0 | 0 | No | No |
| 19065946 | MUSCLE TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF USE THEREOF TO INDUCE EXON SKIPPING OF EXON 44 OF DYSTROPHIN IN A SUBJECT | February 2025 | May 2025 | Allow | 2 | 0 | 1 | Yes | No |
| 19046824 | MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF USE THEREOF TO INDUCE EXON SKIPPING | February 2025 | May 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 19033679 | ANTIBODIES TARGETING IL3 | January 2025 | May 2025 | Allow | 4 | 1 | 1 | No | No |
| 18988612 | SELECTIVE AND POTENT INHIBITORY ANTIBODIES OF MYOSTATIN ACTIVATION | December 2024 | April 2025 | Allow | 4 | 1 | 0 | No | No |
| 18979795 | ANTIBODIES THAT BIND INTERLEUKIN 13 AND METHODS OF USE | December 2024 | May 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18940209 | METHOD OF USING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY TO DELIVER AN OLIGONUCLEOTIDE TO A SUBJECT HAVING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | November 2024 | March 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18939894 | COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF DELIVERING OLIGONUCLEOTIDE TO A SUBJECT | November 2024 | April 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18927497 | POLYPEPTIDE COMPRISING A SINGLE-DOMAIN ANTIBODY VARIABLE REGION THAT BINDS DELTA-LIKE LIGAND 3 (DLL3) AND METHOD OF USE THEREOF TO MAKE A RADIONUCLIDE COMPLEX | October 2024 | April 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18924707 | VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION | October 2024 | February 2025 | Allow | 4 | 1 | 0 | No | No |
| 18896799 | METHOD OF TREATING AN INTERLEUKIN-11-ASSOCIATED OR -MEDIATED FIBROTIC DISEASE OR CONDITION BY ADMINISTERING AN ANTI-INTERLEUKIN-11 RECEPTOR SUBUNIT ALPHA (IL-11RA) ANTIBODY | September 2024 | March 2025 | Allow | 6 | 1 | 1 | No | No |
| 18772062 | TMEM219 ANTIBODIES AND THERAPEUTIC USES THEREOF | July 2024 | October 2024 | Allow | 3 | 1 | 0 | No | No |
| 18759724 | COMPOSITIONS COMPRISING PLN-TARGETING ANTI-TRANSFERRIN RECEPTOR ANTIBODY-POLYNUCLEOTIDES AND METHODS OF USE THEREOF TO TREAT CARDIOMYOPATHY | June 2024 | June 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18656654 | COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE | May 2024 | August 2024 | Allow | 4 | 1 | 1 | No | No |
| 18656672 | MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE | May 2024 | August 2024 | Allow | 4 | 1 | 1 | Yes | No |
| 18651734 | MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHODS OF USE THEREOF TO TARGET DYSTROPHIN AND TO TREAT DUCHENNE MUSCULAR DYSTROPHY | May 2024 | January 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18651002 | NOTCH4 ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATING AIRWAY INFLAMMATION | April 2024 | December 2024 | Allow | 8 | 1 | 0 | No | No |
| 18642478 | APPLICATION OF A NANOBODY TARGETING ON IL-6RA | April 2024 | January 2025 | Allow | 9 | 2 | 0 | No | No |
| 18629444 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE WHICH BINDS CLAUDIN-6 and CLAUDIN-9 | April 2024 | September 2024 | Allow | 6 | 1 | 1 | No | No |
| 18619759 | TNFR2 Agonists with Improved Stability | March 2024 | September 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18695013 | COLLAGEN HYDROLYSATE FOR USE IN PREVENTION AND/OR TREATMENT OF POST INTENSIVE CARE SYNDROME (PICS) | March 2024 | December 2024 | Allow | 9 | 0 | 1 | Yes | No |
| 18606648 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | March 2024 | February 2025 | Allow | 11 | 0 | 0 | No | No |
| 18599838 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | March 2024 | November 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18599860 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | March 2024 | January 2025 | Allow | 10 | 0 | 0 | No | No |
| 18599888 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | March 2024 | January 2025 | Allow | 10 | 0 | 0 | No | No |
| 18599849 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | March 2024 | December 2024 | Allow | 9 | 0 | 0 | No | No |
| 18599924 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | March 2024 | January 2025 | Allow | 11 | 0 | 0 | No | No |
| 18593108 | ANTI-HUMAN INTERLEUKIN-33 MONOCLONAL ANTIBODY AND USE THEREOF | March 2024 | March 2025 | Allow | 12 | 2 | 0 | No | No |
| 18593157 | ANTI-HUMAN THYMIC STROMAL LYMPHOPOIETIN (TSLP) MONOCLONAL ANTIBODY AND USE THEREOF TO TREAT DISEASE | March 2024 | June 2025 | Allow | 15 | 1 | 1 | No | No |
| 18590853 | ANTI-INTERLEUKIN-11 RECEPTOR SUBUNIT ALPHA (IL-11RA) ANTIBODIES | February 2024 | September 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18587502 | BISPECIFIC ANTIBODY THAT BINDS TO CD116 AND CD131 | February 2024 | August 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18585158 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | February 2024 | October 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18444102 | METHODS FOR INHIBITING DIAZEPAM BINDING PROTEIN | February 2024 | February 2025 | Allow | 12 | 2 | 0 | No | No |
| 18431764 | NUCLEIC ACIDS, VECTORS, AND CELLS THAT ENCODE ANTIBODIES AND OTHER PROTEINS THAT BIND FOLATE RECEPTOR ALPHA | February 2024 | January 2025 | Allow | 12 | 1 | 1 | No | No |
| 18429738 | Method for Producing an Active Hepatocyte Growth Factor (HGF) | February 2024 | May 2025 | Allow | 16 | 1 | 0 | No | No |
| 18425844 | ANTI-VTCN1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | January 2024 | June 2025 | Allow | 16 | 2 | 0 | No | No |
| 18417063 | COMPOSITIONS AND METHODS FOR CANCER THERAPY | January 2024 | December 2024 | Abandon | 11 | 1 | 0 | No | No |
| 18412403 | EXOSOMES FOR TARGET SPECIFIC DELIVERY AND METHODS FOR PREPARING AND DELIVERING THE SAME | January 2024 | August 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18542929 | POLYNUCLEOTIDES ENCODING ANTI-GLUCAGON-LIKE PEPTIDE 1 RECEPTOR (GLP1R) ANTAGONIST ANTIBODIES | December 2023 | June 2025 | Allow | 17 | 1 | 1 | No | No |
| 18538465 | ANTI-IL-36 ANTIBODIES AND METHODS OF USE THEREOF | December 2023 | May 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18528957 | METHOD OF TREATING AN OCULAR CONDITION BY ADMINISTERING MULTISPECIFIC ANTIBODIES THAT ACTIVATES TIE2 AND BINDS A RECEPTOR TYROSINE KINASE AGONIST | December 2023 | April 2025 | Allow | 17 | 0 | 1 | No | No |
| 18509252 | BISPECIFIC ANTI-CCL2 ANTIBODIES | November 2023 | April 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18504723 | METHODS OF TREATING AN EYE DISORDER | November 2023 | September 2024 | Allow | 10 | 1 | 0 | No | No |
| 18497432 | FOOD-ALLERGEN SPECIFIC ANTIBODY COMPOSITIONS | October 2023 | August 2024 | Allow | 10 | 1 | 1 | No | No |
| 18496472 | Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders | October 2023 | July 2024 | Allow | 8 | 1 | 0 | No | No |
| 18384230 | HUMANIZED ANTIBODIES RECOGNIZING SORTILIN | October 2023 | May 2024 | Allow | 7 | 1 | 0 | No | No |
| 18383121 | LYOPHILIZED POWDER CONFIGURED FOR RECONSTITUTION AS A LIQUID PHARMACEUTICAL FORMULATION WITH REDUCED VISCOSITY AND METHOD OF PREPARING THEREOF | October 2023 | April 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18486445 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | October 2023 | April 2025 | Allow | 18 | 2 | 0 | Yes | No |
| 18481884 | ANTIBODIES AGAINST TIM3 AND USES THEREOF | October 2023 | March 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18481578 | BINDING AGENTS THAT BIND OX40 (CD134) AND METHOD OF USE THEREOF TO TREAT DISEASE | October 2023 | May 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18376196 | INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18478374 | TREATMENT OF HIDRADENITIS SUPPURATIVA | September 2023 | April 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18475958 | Humanized Anti-GDNF family alpha-receptor 4 (GRF-alpha-4) Antibodies and Chimeric Antigen Receptors (CARs) | September 2023 | December 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18468580 | MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHODS OF DELIVERING OLIGONUCLEOTIDE TO A SUBJECT | September 2023 | April 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18467851 | MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE | September 2023 | April 2024 | Allow | 7 | 1 | 1 | No | No |
| 18367444 | AN AQUEOUS PHARMACEUTICAL FORMULATION INCLUDING A VEGF RECEPTOR FUSION PROTEIN | September 2023 | September 2024 | Allow | 12 | 1 | 0 | No | No |
| 18465145 | NUCLEIC ACIDS ENCODING PEPTIDES THAT BLOCK BINDING OF a2d-1 TO GLUTAMATE RECEPTORS FOR TREATING DISEASES AND DISORDERS | September 2023 | August 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18464025 | ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES | September 2023 | February 2024 | Allow | 5 | 1 | 1 | No | No |
| 18463037 | COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES TO HUMAN ADAMTS5 AND NERVE GROWTH FACTOR | September 2023 | April 2024 | Allow | 7 | 2 | 1 | Yes | No |
| 18461678 | METHODS FOR TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-LAG3 ANTIBODY, AND AN ANTI-TIGIT ANTIBODY | September 2023 | February 2025 | Abandon | 18 | 0 | 0 | No | No |
| 18456323 | ANTIBODIES SPECIFIC FOR HUMAN COMPLEMENT C5A RECEPTOR (C5AR) | August 2023 | April 2024 | Allow | 7 | 1 | 1 | No | No |
| 18450222 | METHODS OF TREATING A SUBJECT SUFFERING FROM RHEUMATOID ARTHRITIS WITH ANTI-TNF THERAPY BASED IN PART ON A TRAINED MACHINE LEARNING CLASSIFIER | August 2023 | April 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18448054 | Heparin-Associated Polypeptides and Uses Thereof | August 2023 | May 2024 | Abandon | 9 | 1 | 0 | No | No |
| 18446018 | METHODS OF EXOGENOUS DRUG ACTIVATION OF CHEMICAL-INDUCED SIGNALING COMPLEXES EXPRESSED IN ENGINEERED CELLS IN VITRO AND IN VIVO | August 2023 | March 2025 | Allow | 19 | 1 | 0 | No | No |
| 18365505 | METHOD OF TREATING AN EYE-RELATED DISORDER BY ADMINISTERING AN ANTI-INTERLEUKIN-4 RECEPTOR ALPHA (ANTI-IL-4RA) ANTIBODY | August 2023 | April 2024 | Allow | 8 | 2 | 1 | Yes | No |
| 18365536 | METHODS FOR TREATING DIGITALLY-IDENTIFIED IL-4/IL-13 RELATED DISORDERS | August 2023 | December 2024 | Abandon | 16 | 2 | 1 | Yes | No |
| 18264181 | MODULATION OF MAMMALIAN CELL LINEAGE BY SYNTHETIC IMMODULINS | August 2023 | May 2025 | Allow | 21 | 1 | 0 | Yes | No |
| 18353182 | COMPOSITION FOR CULTURING NK CELLS AND METHOD FOR CULTURING NK CELLS USING SAME | July 2023 | January 2024 | Allow | 6 | 1 | 0 | No | No |
| 18221658 | METHODS AND MATERIALS FOR EXPANDING ANTIGEN-SPECIFIC T CELLS IN CULTURE | July 2023 | May 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18219336 | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF | July 2023 | March 2025 | Allow | 20 | 1 | 1 | No | No |
| 18347626 | NUCLEIC ACIDS ENCODING FCRN-BINDING ANTIBODIES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF USE THEREOF TO MAKE ANTIBODIES | July 2023 | June 2025 | Allow | 24 | 1 | 0 | No | No |
| 18344311 | ANTIBODIES WITH IMPROVED STABILITY TO INTESTINAL DIGESTION, POLYNUCLEOTIDES THEREOF AND METHODS OF USE THEREOF TO TREAT DISEASE | June 2023 | May 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18344786 | VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION | June 2023 | November 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18341278 | CXCL10 BINDING PROTEINS AND USES THEREOF | June 2023 | April 2025 | Allow | 21 | 1 | 1 | No | No |
| 18339094 | ANTIGEN-BINDING MOLECULES AND USES THEREOF | June 2023 | April 2024 | Allow | 9 | 1 | 1 | No | No |
| 18212542 | METHODS OF TREATING PATIENTS AFFLICTED WITH IRRITABLE BOWEL SYNDROME, INFLAMMATORY BOWEL DISEASE OR CHRONIC GASTROINTESTINAL FUNCTIONAL DISORDERS BASED ON ASSESSMENT OF INTESTINAL BARRIER FUNCTION | June 2023 | April 2025 | Allow | 21 | 1 | 1 | No | No |
| 18339061 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | June 2023 | April 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18337875 | HUMANIZED ANTIBODY SPECIFIC FOR CD22 AND CHIMERIC ANTIGEN RECEPTOR USING THE SAME | June 2023 | March 2025 | Allow | 21 | 0 | 0 | No | No |
| 18337901 | MODULATION OF IFI16 AND STING ACTIVITY | June 2023 | May 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18210873 | THEOPHYLLINE-LOADED COLLAGEN NANOPARTICLES | June 2023 | January 2025 | Abandon | 19 | 3 | 0 | No | No |
| 18335636 | ANTI-CD19 ANTIBODY DRUG CONJUGATES | June 2023 | June 2024 | Allow | 12 | 0 | 1 | Yes | No |
| 18332068 | METHODS FOR REDUCING MIGRAINE FREQUENCY IN A SUBJECT IN NEED THEREOF | June 2023 | October 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18331353 | ENHANCED MSC PREPARATIONS | June 2023 | May 2025 | Allow | 23 | 1 | 0 | Yes | No |
| 18329069 | METHODS OF TREATING PNEUMONIA OR RESPIRATORY FAILURE ASSOCIATED WITH COVID-19 BY ADMINISTERING AN ANTI-LIGHT ANTIBODY | June 2023 | February 2025 | Allow | 20 | 1 | 0 | No | No |
| 18328960 | Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same | June 2023 | October 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18324425 | T CELL RECEPTORS | May 2023 | February 2024 | Allow | 9 | 1 | 0 | No | No |
| 18323543 | METHOD OF INCREASING PROTEIN PRODUCTION IN A CHINESE HAMSTER OVARY PERFUSION CELL CULTURE | May 2023 | April 2025 | Allow | 23 | 1 | 1 | Yes | No |
| 18322927 | HEAVY CHAIN ONLY ANTIBODIES TO PDGF | May 2023 | March 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18321249 | Anti-Jagged Antibodies and Methods of Use | May 2023 | May 2025 | Abandon | 24 | 0 | 1 | No | No |
| 18319901 | METHOD FOR CULTURING TUMOR INFILTRATING LYMPHOCYTES | May 2023 | June 2024 | Allow | 13 | 2 | 1 | Yes | No |
| 18196779 | HIGHLY ACTIVE NK CELL AND USE THEREOF | May 2023 | February 2025 | Allow | 21 | 1 | 0 | No | No |
| 18314205 | IgG Fc-IL2-Ralpha-IL2 fusions and methods of use thereof | May 2023 | January 2024 | Allow | 9 | 2 | 1 | Yes | No |
| 18314576 | DEVICES AND METHODS FOR ISOLATING TUMOR INFILTRATING LYMPHOCYTES AND USES THEREOF | May 2023 | January 2025 | Abandon | 20 | 2 | 0 | No | No |
| 18314117 | ANTIBODIES THAT BIND TO C-TYPE LECTIN DOMAIN FAMILY 2 MEMBER D (CLEC2D) | May 2023 | July 2025 | Allow | 26 | 1 | 1 | No | No |
| 18312897 | ANTI-OPG ANTIBODIES | May 2023 | June 2025 | Allow | 25 | 1 | 1 | No | No |
| 18312045 | INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOF | May 2023 | May 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18311771 | ANTI-CD28 X ANTI-PSMA ANTIBODIES | May 2023 | January 2024 | Allow | 9 | 1 | 0 | No | No |
| 18311082 | LIVER-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES THEREOF | May 2023 | October 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 18309450 | METHOD OF REDUCING OR TREATING FIBROSIS BY ADMINISTERING AN INTERLEUKIN-2/TGF-BETA RECEPTOR FUSION POLYPEPTIDE | April 2023 | February 2025 | Allow | 21 | 1 | 1 | No | No |
| 18307729 | COMPOSITIONS | April 2023 | March 2025 | Abandon | 23 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1647.
With a 19.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Art Unit 1647 is part of Group 1640 in Technology Center 1600. This art unit has examined 14,030 patent applications in our dataset, with an overall allowance rate of 55.9%. Applications typically reach final disposition in approximately 30 months.
Art Unit 1647's allowance rate of 55.9% places it in the 11% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.
Applications in Art Unit 1647 receive an average of 1.68 office actions before reaching final disposition (in the 37% percentile). The median prosecution time is 30 months (in the 41% percentile).
When prosecuting applications in this art unit, consider the following:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.